104 related articles for article (PubMed ID: 33327907)
1. Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part-I).
Kamal MA; Khan MA
Curr Pharm Des; 2020; 26(41):5221-5223. PubMed ID: 33327907
[No Abstract] [Full Text] [Related]
2. Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part III).
Khan MA; Kamal MA
Curr Pharm Des; 2021; 27(32):3423. PubMed ID: 34645372
[No Abstract] [Full Text] [Related]
3. Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part IV).
Khan MA; Kamal MA
Curr Pharm Des; 2021; 27(33):3501. PubMed ID: 34645370
[No Abstract] [Full Text] [Related]
4. Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part II).
Kamal MA; Khan MA
Curr Pharm Des; 2021; 27(9):1121-1122. PubMed ID: 34009111
[No Abstract] [Full Text] [Related]
5. Natural Products and Nutrients against Different Viral Diseases: Prospects in Prevention and Treatment of SARS-CoV-2.
Ali SG; Ansari MA; Alzohairy MA; Almatroudi A; Alomary MN; Alghamdi S; Rehman S; Khan HM
Medicina (Kaunas); 2021 Feb; 57(2):. PubMed ID: 33673004
[TBL] [Abstract][Full Text] [Related]
6. Screening of Natural Products Inhibitors of SARS-CoV-2 Entry.
González-Maldonado P; Alvarenga N; Burgos-Edwards A; Flores-Giubi ME; Barúa JE; Romero-Rodríguez MC; Soto-Rifo R; Valiente-Echeverría F; Langjahr P; Cantero-González G; Sotelo PH
Molecules; 2022 Mar; 27(5):. PubMed ID: 35268843
[TBL] [Abstract][Full Text] [Related]
7. Mulberrofuran G, a Mulberry Component, Prevents SARS-CoV-2 Infection by Blocking the Interaction between SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor.
Kim YS; Kim B; Kwon EB; Chung HS; Choi JG
Nutrients; 2022 Oct; 14(19):. PubMed ID: 36235822
[TBL] [Abstract][Full Text] [Related]
8. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
Nandi S; Roy H; Gummadi A; Saxena AK
Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein.
Wang L; Wu Y; Yao S; Ge H; Zhu Y; Chen K; Chen WZ; Zhang Y; Zhu W; Wang HY; Guo Y; Ma PX; Ren PX; Zhang XL; Li HQ; Ali MA; Xu WQ; Jiang HL; Zhang LK; Zhu LL; Ye Y; Shang WJ; Bai F
Acta Pharmacol Sin; 2022 Apr; 43(4):788-796. PubMed ID: 34349236
[TBL] [Abstract][Full Text] [Related]
10. In silico evaluation of food-derived carotenoids against SARS-CoV-2 drug targets: Crocin is a promising dietary supplement candidate for COVID-19.
Mujwar S; Sun L; Fidan O
J Food Biochem; 2022 Sep; 46(9):e14219. PubMed ID: 35545850
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein.
Zhang S; Go EP; Ding H; Anang S; Kappes JC; Desaire H; Sodroski JG
J Virol; 2022 Feb; 96(3):e0162621. PubMed ID: 34817202
[TBL] [Abstract][Full Text] [Related]
12. Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism.
Shawon J; Akter Z; Hossen MM; Akter Y; Sayeed A; Junaid M; Afrose SS; Khan MA
Curr Pharm Des; 2020; 26(41):5241-5260. PubMed ID: 33155902
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Natural Product with Potent Efficacy Against SARS-CoV-2 by Drug Screening.
Li D; Wang C; Wang S; Mehmood A; Gu J; Cheng X; Chen P; Qiu J; Zhao J; Wang J; Wei D
Interdiscip Sci; 2022 Mar; 14(1):55-63. PubMed ID: 34510373
[TBL] [Abstract][Full Text] [Related]
14. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
Dieterle ME; Haslwanter D; Bortz RH; Wirchnianski AS; Lasso G; Vergnolle O; Abbasi SA; Fels JM; Laudermilch E; Florez C; Mengotto A; Kimmel D; Malonis RJ; Georgiev G; Quiroz J; Barnhill J; Pirofski LA; Daily JP; Dye JM; Lai JR; Herbert AS; Chandran K; Jangra RK
Cell Host Microbe; 2020 Sep; 28(3):486-496.e6. PubMed ID: 32738193
[TBL] [Abstract][Full Text] [Related]
15. Butein as a potential binder of human ACE2 receptor for interfering with SARS-CoV-2 entry: a computer-aided analysis.
Kapoor N; Ghorai SM; Khuswaha PK; Bandichhor R; Brogi S
J Mol Model; 2022 Aug; 28(9):270. PubMed ID: 36001177
[TBL] [Abstract][Full Text] [Related]
16. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
17. Molecular Docking and ADMET Prediction of Natural Compounds towards SARS Spike Glycoprotein-Human Angiotensin-Converting Enzyme 2 and SARS-CoV-2 Main Protease.
Oso BJ; Olaoye IF; Omeike SO
Arch Razi Inst; 2021; 76(3):453-459. PubMed ID: 34824739
[TBL] [Abstract][Full Text] [Related]
18. Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part V).
Kamal MA; Khan MA
Curr Pharm Des; 2022; 28(12):947. PubMed ID: 35796442
[No Abstract] [Full Text] [Related]
19. Alkaloids: Therapeutic Potential against Human Coronaviruses.
Fielding BC; da Silva Maia Bezerra Filho C; Ismail NSM; Sousa DP
Molecules; 2020 Nov; 25(23):. PubMed ID: 33255253
[TBL] [Abstract][Full Text] [Related]
20. Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.
Toor HG; Banerjee DI; Lipsa Rath S; Darji SA
Eur J Pharmacol; 2021 Jan; 890():173720. PubMed ID: 33160938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
